Biotech veteran Tony Coles to become CEO of Pfizer neuroscience spinout Cerevel
by Matthew Herper
Sep 09, 2019
1 minute
Tony Coles, remembered by many investors for engineering a $10 billion biotech deal in 2013, will become chief executive of Cerevel, the Pfizer neuroscience spinout to which Bain Capital has pledged up to $350 million
You’re reading a preview, subscribe to read more.
Start your free 30 days